Nuclear Pharmacy Services

After a decade of failures, convergence – the merging of formerly distinct market segments for pharmaceuticals, diagnostics, and medical devices – has become a powerful new growth opportunity in healt

In this issue, we present another installment of our quarterly review of dealmaking—for April-June 2002. Our data comes from Windhover's Strategic Transactions Database , which covers deal activity w

The complexity of delivering this drug to patients makes success even harder to predict than for most new oncology products. by Mark L. Ratner By all accounts, the management team at Idec Pharmaceuti

Molecular imaging is progressing into the clinic, but as in the research world, a host of thorny questions has yet to be resolved before opportunities can be optimized. By Wendy Diller In February of